Navigation Links
Danish Hotspot in Personalized Medicine
Date:11/12/2007

COPENHAGEN, November 12 /PRNewswire/ -- The Danish biotech cluster known as Medicon Valley has, within a short period, grown into a global hotspot in the field of personalized medicine, and finds itself increasingly in favor among big pharma and big biotech. Experience Danish competencies at the 3rd Annual Personalized Medicine Meeting in San Francisco from 12th - 13th November.

With over 10 research institutions and 15-20 private companies engaged in personalized medicine, the Danish biotech cluster known as Medicon Valley has in record time become a strong player in currently one of the hottest research fields within the pharmaceutical industry.

Several of these Danish players operate on an individual basis, although many are also involved in collaborative research efforts, including the Danish Center for Translational Breast Cancer Research, the siRNA Delivery Center, the Danish microRNA consortium and special research departments at the University of Copenhagen and the Technical University of Denmark.

This is one reason why Denmark is participating in 3rd Annual Personalized Medicine Meeting in San Francisco, where Director of Knowledge and Communications at Danish Medicines Agency Kaare Geil is in the panel discussion on the second day to give a European/Danish perspective on the topic: Who Will Pay? The Economics of Personalized Medicine. Kaare Geil says: "Denmark has a national cancer plan, which is very clear on personalized medicine. The ministry of health as well as the ministry of science, has specific programs to support and enable the implementation of personalized medicines in our systems."

S0ren M. Echwald, M.Sc., Ph.D., who is Vice President and responsible for Business Development at Exiqon will be hosting a table discussion at the conference. "Exiqon is very committed to our diagnostic vision, and is active with several diagnostic projects," says S0ren M. Echwald. "With Exqion's key technologies, the growing role of m
'/>"/>

SOURCE Copenhagen Capacity
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
2. HHS Issues First Department-Wide Report on Personalized Health Care
3. Agendia Joins the Personalized Medicine Coalition (PMC)
4. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
5. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
8. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
9. Companys Partner Completes Trial Production of a New Antiviral Medicine
10. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
11. Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 2Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4